This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Greenlee, K. M. Search for Related Content Social Bookmarking                         What's this?

New Oral Anticoagulants

Cleveland Clinic Foundation, Department of Pharmacy/QQb5, 9500 Euclid Avenue, Cleveland, OH 44195, greenlk{at}ccf.org

The risk of bleeding, narrow therapeutic index, and need for routine monitoring make oral anticoagulation with warfarin a less than ideal oral anticoagulant. Intravenous therapies such as heparin are not orally bioavailable and have a narrow therapeutic index and high risk of bleeding. New oral antico agulants currently under investigation may have more ideal characteristics for long-term administration. The mechanism of thrombogenesis, limitations of current therapy, and new investigational oral anticoagulants are discussed.

Key Words: oral anticoagulation • heparin • direct thrombin inhibitor • warfarin • ximelagatran

Journal of Pharmacy Practice, Vol. 15, No. 4, 369-376 (2002)
DOI: 10.1177/089719002129041359


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?